WO2024176106 - IMPROVED METHODS FOR SYNTHESIS OF 5-(AMINOMETHYL)PYRROLIDIN-2-ONE COMPOUNDS
National phase entry is expected:
Publication Number
WO/2024/176106
Publication Date
29.08.2024
International Application No.
PCT/IB2024/051607
International Filing Date
20.02.2024
Title **
[English]
IMPROVED METHODS FOR SYNTHESIS OF 5-(AMINOMETHYL)PYRROLIDIN-2-ONE COMPOUNDS
[French]
PROCÉDÉS AMÉLIORÉS DE SYNTHÈSE DE COMPOSÉS DE 5-(AMINOMÉTHYL)PYRROLIDIN-2-ONE
Applicants **
ARBUTUS BIOPHARMA CORPORATION
Inventors
MASON, Jeremy
Priority Data
63/447,143
21.02.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2744 | |
| EPO | Filing, Examination, Granting | 22811 | |
| Japan | Filing, Examination, Granting | 2831 | |
| South Korea | Filing, Examination, Granting | 3598 | |
| USA | Filing, Examination, Granting | 8140 |
Total:
40,124
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to scalable methods for synthesis of 5-(aminomethyl)pyrrolidin-2-one compounds that are useful intermediates in the synthesis of biologically active compounds, including programmed death ligand 1 (PD-L1) inhibitors. In certain embodiments, the 5- (aminomethyl)pyrrolidin-2-one compound is (S)-5-(aminomethyl)pyrrolidin-2-one. The methods described herein permit the synthesis of 5- (aminomethyl)pyrrolidin-2-one compounds without the use of dangerous, toxic, and/or otherwise undesirable reagents and solvents. The methods described herein also permit the synthesis of 5-(aminomethyl)pyrrolidin-2-one compounds without the use of dangerous and/or otherwise undesirable reaction conditions. The synthesis of 5-(aminomethyl)pyrrolidin-2-one compounds is without the need for column chromatography.[French]
La présente invention concerne des procédés évolutifs pour la synthèse de composés de 5- (aminométhyl)pyrrolidin-2-one qui sont des intermédiaires utiles dans la synthèse de composés biologiquement actifs, comprenant des inhibiteurs de ligand de mort programmée 1 (PD-L1). Dans certains modes de réalisation, le composé de 5-(aminométhyl)pyrrolidin-2-one est (S)-5-(aminométhyl)pyrrolidin-2-one. Les procédés décrits ici permettent la synthèse de composés de 5-(aminométhyl)pyrrolidin-2-one sans utiliser de réactifs et de solvants dangereux, toxiques et/ou autrement indésirables. Les procédés décrits ici permettent également la synthèse de composés de 5-(aminométhyl)pyrrolidin-2-one sans utiliser de conditions de réaction dangereuses et/ou autrement indésirables. La synthèse de composés de 5-(aminométhyl)pyrrolidin-2-one est sans nécessiter de chromatographie sur colonne.